Alkermes' (ALKS) Nemvaleukin Alfa Granted FDA Fast Track Designation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Pre-Open Stock Movers 08/02: (XCUR) (DLPN) (AUTL) Higher; (PH) (SQ) Lower (more...)
August 2, 2021 9:31 AM EDTPre-Open Stock Movers:
Exicure Inc. (NASDAQ: XCUR) 35.5% HIGHER; Ipsen (Euronext: IPN; ADR: IPSEY) and Exicure Inc. (NASDAQ: XCUR) have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments for Huntingtons disease and Angelman syndrome.
Dolphin Entertainment (NASDAQ: DLPN) 27% HIGHER; Hall of Fame Resort and Entertainment Company (NASDAQ: HOFV, HOFVW) and Dolphin Entertainment (NASDAQ: DLPN) announce the creation of a new NFT... More
Alkermes (ALKS) Granted FDA Fast Track Designation for Nemvaleukin Alfa
August 2, 2021 7:02 AM EDTAlkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nemvaleukin alfa (nemvaleukin), the company's novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy, for the treatment of mucosal melanoma. Earlier this year, the FDA also granted... More
Alkermes (ALKS) PT Raised to $33 at Mizuho Securities
July 29, 2021 6:33 AM EDTMizuho Securities analyst Vamil Divan raised the price target on Alkermes (NASDAQ: ALKS) to $33.00 (from $29.00) while maintaining a Buy rating.... More
